BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8617578)

  • 1. A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
    Meropol NJ; Petrelli NJ; Rustum YM; Rodriguez-Bigas M; Blumenson LE; Frank C; Berghorn E; Creaven PJ
    Invest New Drugs; 1995; 13(2):149-55. PubMed ID: 8617578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
    Punt CJ; Kamm YL; Wagener DJ
    Anticancer Drugs; 1997 Jun; 8(5):454-8. PubMed ID: 9215607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    de Gramont A; Louvet C; André T; Tournigand C; Krulik M
    Eur J Cancer; 1998 Apr; 34(5):619-26. PubMed ID: 9713264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
    Joulia JM; Pinguet F; Ychou M; Duffour J; Astre C; Bressolle F
    Eur J Cancer; 1999 Feb; 35(2):296-301. PubMed ID: 10448274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
    Cao S; Frank C; Rustum YM
    J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
    Machover D; Grison X; Goldschmidt E; Zittoun J; Lotz JP; Metzger G; Richaud J; Hannoun L; Marquet J; Guillot T
    J Natl Cancer Inst; 1992 Mar; 84(5):321-7. PubMed ID: 1738182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
    Mackean MJ; Cassidy J; Jodrell DI; Paul J; Reed NS; Canney PA; Yosef H; Habeshaw T; Robertson AG; McInnes A; Twelves CJ
    Br J Cancer; 1998 May; 77(9):1480-6. PubMed ID: 9652765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of subcutaneous 5-fluorouracil: a case report.
    Eatock MM; Carlin W; Dunlop DJ; Soukop M; Watson DG
    Cancer Chemother Pharmacol; 1996; 38(1):110-2. PubMed ID: 8603444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Zaniboni A
    J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
    Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
    Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
    Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
    Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
    Machover D; Grison X; Goldschmidt E; Zittoun J; Metzger G; Richaud J; Lotz JP; André T; Hannoun L; Marquet J
    Ann Oncol; 1993; 4 Suppl 2():29-35. PubMed ID: 8353102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.